Back to homepage

Health Economics & Outcomes Research

Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis

Authors: Christophe Sapin, Ann Hartry, Siddhesh A Kamat, Maud Beillat, Ross A Baker, Anna Eramo

In this analysis the authors used health economics assessment data collected during the QUAlity of LIfe with AbiliFY Maintena (QUALIFY) study, a randomized head-to-head study of aripiprazole once-monthly 400 mg (AOM 400) compared with paliperidone palmitate (PP; 78–234 mg/mo), to determine the direct medical and pharmacy costs and the cost-effectiveness associated with each treatment over 6 months. The authors concluded that the analysis of data from stabilized patients with schizophrenia in the QUALIFY study indicated that AOM 400 is associated with lower health-care costs and greater effectiveness compared with PP and thus represents the economically dominant strategy.

More

Evaluating cost benefits of combination therapies for advanced melanoma

Authors: Ivar S Jensen, Emily Zacherle, Christopher M Blanchette, Jie Zhang, Wes Yin

The model presented in this study was used to analyze the clinical and economic benefit of using combination therapies in advanced melanoma patients with the BRAF V600 mutation. The analysis suggests dabrafenib + trametinib therapy is associated with less patient time and lower costs relative to nivolumab + ipilimumab to gain similar progression-free survival and overall response rate benefits.

More

Clinical and cost outcomes from different hyaluronic acid treatments in patients with knee osteoarthritis: evidence from a US health plan claims database

Authors: Vinod Dasa, Mitch DeKoven, Kainan Sun, Allan Scott, Sooyeol Lim

Intra-articular injection of hyaluronic acid (HA) for knee osteoarthritis (OA) effectively reduces pain and delays total knee replacement (TKR) surgery; however, little is known about relative differences in clinical and cost outcomes among different HA products. In this study, the authors conclude that analysis of administrative claims data provides real-world evidence that meaningful differences exist among some HA products in disease-specific cost and time to knee replacement surgery.

More

Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia

Authors: Michele Wilson, Benjamin Gutierrez, Steve J Offord, Christopher M Blanchette, Anna Eramo, Stephanie Earnshaw, Siddhesh A Kamat

Schizophrenia is associated with high direct healthcare costs due to progression of disease and frequent occurrence of relapses. Aripiprazole once-monthly (AOM) has been shown to reduce total psychiatric hospitalizations among patients who switched from oral standard of care (SOC) therapy to AOM. In this paper the authors report the results of an economic model study to evaluate the psychiatric hospitalization-related medical costs and antipsychotic pharmacy costs during a 6-month period before and after initiation of AOM treatment.

More

An assessment of chemotherapy-induced nausea and vomiting direct costs in three EU countries

Authors: Marco Turini, Vittoria Piovesana, Pierfrancesco Ruffo, Claudio Ripellino, Nazarena Cataldo

Inadequately treated, chemotherapy-induced nausea and vomiting (CINV) can lead to increased resource utilization and severely impair patients’ daily functioning and quality of life. The authors investigated the management of CINV episodes in three European health-care environments and estimate the direct costs associated with severe CINV episodes.

More